Analysts Offer Insights on Healthcare Companies: Portola Pharma (NASDAQ: PTLA) and Danaher Corp (NYSE: DHR)

By Carrie Williams

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Portola Pharma (NASDAQ: PTLA) and Danaher Corp (NYSE: DHR) with bullish sentiments.

Portola Pharma (NASDAQ: PTLA)

In a report released today, Vamil Divan from Credit Suisse maintained a Buy rating on Portola Pharma (NASDAQ: PTLA), with a price target of $49. The company’s shares closed yesterday at $38.03.

According to TipRanks.com, Divan is a 1-star analyst with an average return of -1.8% and a 45.4% success rate. Divan covers the Healthcare sector, focusing on stocks such as Corvus Pharmaceuticals Inc, Allena Pharmaceuticals Inc, and Alder Biopharmaceuticals.

Currently, the analyst consensus on Portola Pharma is Strong Buy and the average price target is $57.80, representing a 52.0% upside.

In a report issued on March 1, William Blair also maintained a Buy rating on the stock.
Danaher Corp (NYSE: DHR)

In a report released today, Erin Wright from Credit Suisse maintained a Buy rating on Danaher Corp (NYSE: DHR), with a price target of $108. The company’s shares closed yesterday at $103.40, close to its 52-week high of $104.82.

According to TipRanks.com, Wright is a 5-star analyst with an average return of 12.8% and a 75.9% success rate. Wright covers the Services sector, focusing on stocks such as AmerisourceBergen Corporation, Patterson Companies Inc, and Quest Diagnostics Inc.

Danaher Corp has an analyst consensus of Strong Buy, with a price target consensus of $108.90.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.